Re: Falk Symposium 155 - Highlights

[Guest guest]

,

I agree that the abstracts are a reason for much optimism. I

especially see the 4th (in part, below) providing a strong reason to

start ursodeoxycholic acid early. That no incidence of CCA was seen

after 8.5 years of treatment seems like a fantastically good result.

Tim R

> Abstracts from the Falk Symposium 155. XIII Falk Liver Week

....

>

> The incidence of cholangiocarcinoma in primary sclerosing

> cholangitis during longtime treatment with ursodeoxycholic acid.

>

> A. Stiehl

>

> Department of Medicine, University of Heidelberg, Germany

>

> Results: ... The calculation of CCA per patient years revealed

> 0.58 CCA per 100 patient years in years 0–2.5, 0.49 CCA in

> years 2.5–8.5, and no CCA thereafter up to 18 years after entry

> into the study. ...

>

> Summary and conclusion: The annual incidence rate of CCA in PSC

> treated with UDCA is low and decreases with time of treatment.

> Compared with the CCA incidence rates reported in studies on the

> natural course of the disease, the CCA incidence after UDCA

> treatment was lower than expected.